Orionis Biosciences develops first‑in‑class immunotherapies and targeted small molecules using its proprietary A‑Kine™ biologics and Allo‑Glue™ molecular glue platforms. The company aims to engineer conditionally active, target‑selective cytokines to trigger anti‑tumor immune responses while avoiding systemic toxicities. Its Allo‑Glue platform pursues genome‑scale discovery and rational design of molecular glues to reach previously intractable targets. Orionis has built a deep pipeline, cemented a drug discovery deal with Novartis, and plans to advance lead cancer immunotherapy programs into clinical trials. The company presented preclinical molecular glue data at the 5th Annual Targeted Protein Degradation conference in October 2022. The completed financing will fund R&D expansion, pipeline growth and progression of programs toward the clinic.

Total raised

$55M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2022